Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Phase II Pilot Study to Evaluate the Efficacy and Safety of Recombinant Super-compound Interferon (rSIFN-co) Among Healthy Subjects in Close Contact With Confirmed COVID-19 Case(s) and Subjects With Mild or Asymptomatic COVID-19

NCT05485584 is registered in ClinicalTrials.gov with Sichuan Huiyang Life Science and Technology Corporation as lead sponsor.

NCT NCT05485584
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05485584 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Phase II Pilot Study to Evaluate the Efficacy and Safety of Recombinant Super-compound Interferon (rSIFN-co) Among Healthy Subjects in Close Contact With Confirmed COVID-19 Case(s) and Subjects With Mild or Asymptomatic COVID-19
Lead sponsor
Sichuan Huiyang Life Science and Technology Corporation
Phase
Phase 2
Overall status
Completed
Start date
July 1, 2022
Completion date
April 5, 2023
Enrollment
188 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19, sars-cov-2 infection